GLP-1 Drugs Like Ozempic Linked to Gallstones and Acid Reflux in Major Review

This landmark meta-analysis provides the most comprehensive safety assessment of GLP-1 receptor agonists to date, addressing growing concerns about gastrointestinal side effects as these medications become increasingly popular for diabetes and weight management.

Researchers analyzed 55 randomized controlled trials involving 106,395 participants across multiple conditions including type 2 diabetes, obesity, and fatty liver disease. They systematically evaluated 15 different gastrointestinal and biliary adverse events, comparing GLP-1 drugs to placebo using rigorous statistical methods.

The study found two statistically significant increased risks: gallstones (cholelithiasis) with a 46% relative increase, and GERD with a 119% relative increase. However, the absolute risk increases were modest - approximately 2 additional gallstone cases and 4 additional GERD cases per 1,000 patients treated. Importantly, GLP-1 drugs did not increase risks of more serious complications like pancreatitis, intestinal obstruction, or gastrointestinal bleeding.

Subgroup analyses revealed that risks were more pronounced in patients using these medications primarily for weight loss, those receiving higher doses, and patients with obesity or fatty liver disease, though these differences weren't statistically significant. The findings suggest that while GLP-1 drugs carry some gastrointestinal risks, they appear safer than previously feared regarding serious complications. For clinicians, this data supports careful patient selection and monitoring, particularly for gallbladder disease in high-risk populations, while providing reassurance about the overall gastrointestinal safety profile of these increasingly important medications.